#### **ORIGINAL ARTICLE**



# Laparoscopic surgery may decrease the risk of clinical anastomotic leakage and a nomogram to predict anastomotic leakage after anterior resection for rectal cancer

Hongtu Zheng <sup>1,2</sup> • Zhenyu Wu <sup>3</sup> • Yuchen Wu <sup>1,2</sup> • Shanjing Mo <sup>1,2</sup> • Weixing Dai <sup>1,2</sup> • Fangqi Liu <sup>1,2</sup> • Ye Xu <sup>1,2</sup> • Sanjun Cai <sup>1,2</sup>

Accepted: 12 November 2018 / Published online: 23 November 2018 © The Author(s) 2018

#### **Abstract**

**Introduction** Anastomotic leakage is still one of the most dreaded complications after anterior resection for rectal cancer. This study aimed to identify risk factors for anastomotic leakage and to create a nomogram for precise prediction of anastomotic leakage after anterior resection for rectal cancer.

**Methods** Two thousand six hundred eighteen consecutive patients who underwent anterior resection for rectal cancer with primary anastomosis, with or without diverting stoma, were retrospectively analyzed as a training dataset. Univariate and multivariable Cox regression analyses were used to determine independent risk factors associated with anastomotic leakage. A nomogram was constructed to predict anastomotic leakage. Data containing 611 patients were prospectively collected as a test dataset. The performance of the nomogram was evaluated by using a bootstrapped-concordance index and calibration plots.

**Results** The rate of clinical anastomotic leakage was 9.3% in the training dataset. Multivariate analysis identifies the following variables as independent risk factors for anastomotic leakage: gender (male) (odds ratio (OR) = 2.286), distance of tumor to anal verge (OR = 0.791), tumor size (OR = 1.175), operating time (OR = 1.009), diabetes mellitus (OR = 1.704), laparoscopic surgery (OR = 0.445), anastomotic bleeding (OR = 13.46), and diverting stoma (OR = 0.386). We created a nomogram with high discriminative ability (concordance index, 0.722). The area under the curve value, which evaluated the predictive performance of external validation, was 0.723.

**Conclusions** A protective diverting stoma and laparoscopic surgery significantly decrease the risk of anastomotic leakage. Our nomogram was a useful tool for precise prediction of anastomotic leakage after anterior resection for rectal cancer.

Keywords Anastomotic leakage · Rectal cancer · Risk factor · Nomogram · Laparoscopic surgery

Hongtu Zheng and Zhenyu Wu contributed equally to this work and should be regarded as first co-authors.

- Ye Xu xuye021@163.com
- Sanjun Cai caisanjun sh@163.com

Hongtu Zheng 0356153@fudan.edu.cn

Zhenyu Wu wzy107@126.com

Yuchen Wu 17111230031@fudan.edu.cn

Shanjing Mo moshanjingfd@126.com Weixing Dai daiweixing2015@163.com

Fangqi Liu 12131230023@fudan.edu.cn

- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
- Department of Biostatistics, School of Public Health, Key Laboratory of Public Health Safety and Collaborative Innovation Center of Social Risks Governance in Health, Fudan University, Shanghai, China



## Introduction

Colorectal cancer is the third most commonly diagnosed cancer and is the third leading cause of cancer-related deaths worldwide. In developing countries, the incidence of colorectal cancer has significantly increased [1]. Anterior resection (AR), as known as Dixon operation, is the major surgical treatment for rectal cancer.

Anastomotic leakage (AL) is still the most dreaded surgical complication following AR, with an incidence rate of 1.6–20.5% [2–11]. AL is associated with increased postoperative mortality, length of hospitalization, and hospital-related costs. Some of the patients with AL may require a temporary or permanent stoma, which significantly affects patients' quality of life [12–15]. Furthermore, studies have shown that AL increases local recurrence rates and reduces cancer-specific survival [12, 16], which may be due to a delay of adjuvant therapy in patients with AL.

Many risk factors for anastomotic leakage have been reported; however, it is still difficult to predict anastomotic leakage accurately. Dekker et al. [17] retrospectively analyzed the AL risk factors in 138 patients with left-sided colon cancer and developed an AL scoring system. Frasson et al. [18] analyzed the AL risk factors in 3193 patients with colon cancer and created a devised nomogram to predict the risk of AL. However, the nomogram model can only be utilized in patients with colon cancer. Similarly, Yao et al. [9] and Kim et al. [19] constructed nomogram models as a tool for predicting the risk of AL after laparoscopic surgery of rectal cancer; however, the weights used in their reported nomogram models were different. To date, an accurate risk-predicting model for AL after AR has not been established.

The aim of this study was to create a precise and reliable nomogram for predicting the risk of AL after AR.

## Materials and methods

#### **Patients**

Patients who underwent AR at the Shanghai Cancer Center because of rectal cancer from January 2010 to February 2016 were included in our study. Exclusion criterion included a previous history of colon or rectal resection, and patients with tumors > 12 cm from the anal verge were excluded. This study was approved by the Research Ethics Committee of the Cancer Hospital, Fudan University. Collection of patients' follow-up data was conducted in accordance with guidelines for the collection of human follow-up data from the Cancer Hospital, Fudan University. All patients provided written informed consent.

Overall, 2618 patients were finally recruited into our following analysis to establish the nomogram model. Then, 611 patients who underwent AR from March 2016 to April 2017 in our institution were prospectively collected as a group for external validation.



#### **Definition of AL**

Clinical anastomotic leakage was considered to be present if any of the following were observed: gas or fecal discharge from the incisional wound, vagina, or the drain tract; fecal peritonitis; or intraabdominal abscess or peritonitis along with an anastomotic defect verified by image study, sigmoidoscopy, at laparotomy, or rectal examination. A pelvic abscess near the anastomotic site without an obvious fecal fistula was also classified as a clinical leakage [4].

Based on the system proposed by the International Study Group of Rectal Cancer (ISREC), the degree of anastomotic leakage was classified into three categories: grade A required no active therapeutic intervention; grade B required active therapeutic intervention without the necessity of relaparotomy; and grade C required re-laparotomy [20]. In the present study, clinical AL was classified as grade B or C.

# Statistical analysis

Patient-related, tumor-related, and surgery-related variables were collected as potential risk factors for AL in the univariate and multivariate analysis.

Most associations with AL, with regard to demographic and clinicopathologic features, were evaluated using multivariate logistic regression analysis. We used a stepwise selection method (sle = 0.05, sls = 0.10) to select a subset of all analyzed features. In the final model, only the features that were statistically significant at the 0.05 level were retained.

The nomogram performance was composed of two components: discrimination and calibration. The ability of a model to separate subject outcomes is known as discrimination. Discrimination was quantified with the concordance index (Cindex), which is similar to the area under the receiver operating characteristic (ROC) curve [21]. Calibration was performed by comparing the predicted probability of AL versus the actual probability of AL in all patients [22], again using 500 bootstrap re-samples to reduce overfit bias, which would overstate the accuracy of the nomogram. We validated the nomograms with an external independent validation set, and the predictive performance was evaluated by the AUC value of the ROC analysis. Statistical analyses were performed using SPSS22.0, SAS 9.1, and R software version 3.1.2 (http://www.r-project.org) with the rms package. P values of 0.05 or lower were considered statistically significant.

# Results

A total of 2618 patients were retrospectively collected as a training dataset. The incidence of clinical AL was 9.3% (243/2618), among which the incidence rates of grade B and grade C AL were 6.3% (165/2618) and 3.0% (78/2618), respectively.

Additionally, 374 patients (14.3%) received neoadjuvant radio(chemo)therapy, 395 patients (15.1%) underwent laparoscopic surgery, and 444 patients (17.0%) underwent construction of a diverting stoma (DS) during the surgery.

The following variables were found to be associated with AL in univariate analysis: distance of tumor to anal verge, tumor size, duration of operation, preoperative hemoglobin level, blood loss, male, diabetes mellitus, bowel obstruction, ASA score, laparoscopic surgery, and anastomotic bleeding. The clinical information and results of the univariate analysis of patients in the training dataset are listed in Table 1.

The following variables were identified as independent risk factors of AL in multivariate analysis: gender (male) (P < 0.0001, odds ratio (OR) = 2.286), distance of tumor to anal verge (P < 0.0001, OR = 0.791), tumor size (P = 0.006, OR = 1.175), operating time (P < 0.001, OR = 1.009), diabetes mellitus (P = 0.041, OR = 1.704), laparoscopic surgery (P = 0.004, OR = 0.445), anastomotic bleeding (P < 0.001, OR = 13.46), diverting stoma (P < 0.001, OR = 0.386) (Table 2). A nomogram using these risk factors as weights is shown in Fig. 1.

In the test dataset of 611 patients, the incidence of clinical AL was 10.5% (64/611). The incidence rates of grade B and grade C AL were 9.2% (56/611) and 1.3% (8/611), respectively. Additionally, 21.8% of these patients received neoadjuvant therapy (133/611), which was higher than 14.3% in the training dataset. In all, 43.4% (265/611) of these patients underwent laparoscopic surgery, which was higher than 15.1% in the training dataset. The incidence of DS in the test dataset was also higher than that in the training dataset (36.5% vs 17.0%, respectively). The reason for the differences between the two datasets dues to a more prevalent application of neoadjuvant therapy and laparoscopic surgery in our institution during the past few years, and patients who received neoadjuvant therapy or underwent low anterior resection (LAR) were more likely to receive a DS during surgery.

We validated the predicted efficiency of the created nomogram model using these 611 patients as a test dataset. The clinical information and identified risk factors associated with AL in the test dataset are listed in Table 3. The nomogram that integrated all objective risk factors for AL is shown in Fig. 1. The C-index for AL prediction was 0.722 (0.720–0.724) in the model. The calibration plot for the incidence of AL showed an optimal agreement between the prediction by the nomogram and the actual observation (Fig. 2). ROC analysis confirmed the diagnostic potential of the nomogram. The model yielded an AUC of 0.723.

# **Discussion and conclusion**

In this study, 2618 consecutive patients who underwent anterior resection for rectal cancer were collected to identify risk

factors for anastomotic leakage. The multivariate analysis identifies the following variables as independent risk factors for anastomotic leakage: gender (male), distance of tumor to anal verge, tumor size, operating time, diabetes mellitus, laparoscopic surgery, anastomotic bleeding, and diverting stoma (Table 2). We created a nomogram with high discriminative ability.

In previous studies, there were significant variations in the incidence rates of AL after colorectal resection, ranging from 1.6 to 20.5% [2–11]. In general, the incidence of AL increases after AR compared to colon surgery. In 2016, a prospective study by Park et al. [23] showed AL rates of 5.6% (219/3912) and 1.1% (71/6565) after rectal and colon surgery, respectively. In addition, AL can be classified into asymptomatic subclinical AL and symptomatic clinical AL that requires active treatment. In 2009, ISREC classified AL into three grades (grades A, B, and C) based on its severity and required treatment regimens [20]. In 2011, Maggiori et al. [2] conducted a retrospective study that showed a total AL rate of 20.5% (41/ 200), of which 13.5% (27/200) accounted for clinical AL and 7% (14/200) for asymptomatic AL. In 2015, Shiomi et al. [24] reported a total AL rate of 15.9% (149/936), of which 12.9% (121/936) accounted for grades B and C. In 2016, a prospective study by Qin et al. [25] showed a total AL rate of 17.0% (54/318) after AR, with a clinical AL rate of 9.7% (31/318). However, most studies only included grades B and C. The significant difference in AL rates was attributable not only to the different ratios of the participants who underwent colon and rectal surgery but also to the inconsistent inclusion criteria for AL. In our center, the AL rates were relatively low: the incidence rate of grades B and C after resection was 6.83%, of which the incidence rates of grade B AL and grade C AL were 5.1% and 1.7%, respectively.

Our multivariate analysis showed that the postoperative risk for AL was significantly higher in male patients (adjusted OR = 2.29). Other studies obtained similar results (OR = 1.49–3.2) [5, 18, 23, 24]. The higher risk of AL in male patients may be due to their narrow pelvis, which leads to a more complicated operation compared to female patients with a broader pelvis. Some studies also showed that androgen might exert inhibitory effects on intestinal epithelial function. However, a significant association between sex and AL was not observed in other studies [25, 26]. Other patient-related risk factors, including medical history and preoperative nutritional status, were not found to be independent risk factors for AL in the present multivariate analysis.

Numerous studies found that the distance of the tumor or the anastomosis to the anal verge is closely associated with AL [5, 23, 27]. However, these studies only classified the patients into two or three groups based on the distance from the anastomosis to the anal verge. For example, Yeh et al. [4] and Jestin et al. [28] showed a significant increase in AL risk when the distance between the anastomosis and the anal verge was



 Table 1
 Univariate analysis of variables related to anastomotic leakage (training dataset)

BML kgm² (mage)         23.1 (4.6-38.3)         23.1 (4.6-38.3)         0.05.0           Distance of tumor oam levege. (m (range))         13.0 (3-14)         3.9 (0.5-11)         4.1 (0.8-14)         0.000           Tumor sic, cm (range)         3.9 (0.5-14)         3.9 (0.5-11)         4.1 (0.8-14)         0.000           Dumation of operative hemoglobin, gl.         117.1 (2.8-81)         116.1 (31-818)         118.2 (23-29.3)         0.000           Properative hamoglobin, gl.         424 (26-64.4)         42.2 (26-54.4)         42.2 (26-54.3)         0.000         7.00 -500)         0.000           Blood lost, ml. (range)         16.0 (-0000)         6.0 (0-1000)         7.00 -500)         0.00         0.00           Caragórical variables of Pasis information         18.5         15.1         185         185         4.00           Male         15.56         1351         185         8         4.00         180         185         4.00         180         185         4.00         180         185         4.00         180         185         4.00         180         185         4.00         180         185         4.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.0	Categorical variables	All patients ( $N = 2618$ )	Patients without AL $(N = 2375)$	Patients with AL $(N = 243)$	P value
BML kgm² (mage)         23.1 (4.6-38.3)         23.1 (4.6-38.3)         0.05.0           Distance of tumor to anal verge, cm (range)         11.2 (-12)         13.0 (-12)         12.0 (-12)         12.0 (-12)         12.0 (-12)         10.0 (-14)         0.000           Duration of operation, min (range)         117.1 (2.4-81)         116.1 (31-481)         12.8 (23-292)         0.000           Dructorio of perative hemoglobin, gl.         130.4 (52-183)         130.1 (52-183)         133.2 (53-176)         0.010           Blood lost, ml. (range)         16.6 (-1000)         64.8 (0-1000)         73.1 (0-1000)         0.03           Peroperative hemoglobin, gl.         12.6 (-64-4)         42.2 (26-54.4)         42.5 (26-45.4)         42.5 (26-45.4)         42.5 (26-45.4)         42.5 (26-45.4)         42.5 (26-45.4)         42.6 (26-54.4)         42.5 (26-45.4)         42.6 (26-54.4) <td></td> <td></td> <td></td> <td></td> <td></td>					
Distance of numor to anal vege, em (emge)         11.2 (0-12)         \$1.2 (0-12)         \$0.05.14)         3.9 (05-11)         4.1 (08-14)         0.025           Duration of operation, min (range)         11.1 (124-881)         116.1 (13-481)         128.4 (23-929)         0.000           Prespentive Indumin, gl.         130.4 (52-183)         130.1 (52-183)         133.2 (23-70)         0.001           Prespentive albumin, gl.         42.4 (26-544)         42.4 (26-544)         42.5 (29-43-43)         0.001           Blood lost, mil. (range)         0.10-1000         0.0 (0-1000)         7.0 (0-500)         0.03           Pernoperitye blood transition, ml. (range)         0.10-1000         0.0 (0-1000)         7.0 (0-500)         0.05           Female         1082         1024         8         8         0.001           Female         1082         1024         8         8         0.001           Make         155         1851         185         185         185         185         185         185         185         185         185         185         180         185         185         185         180         185         180         185         185         180         185         180         180         180         180					0.557
Tumer size, cm (range)         3,9 (0.5-14)         3,9 (0.5-11)         4,1 (0.8-14)         0.025           Dumbino in operation, min (range)         117.0 (4.2-481)         116.1 (31-481)         128.4 (2.3-2-2)         <0.000					
Dumation of operation, min (range)   117.1 (23-481)   116.1 (31-481)   123.4 (22-292) < 0.001     Proopentive hamplobins, gl.					
Peopentive hemoglobins gL					
Peopentive albumin; g.l.					
Blood lost, mf. (mage)					
Perioperative blood transfission, mil. (range)         6.1 (0-1000)         6.0 (0-1000)         7.0 (0-500)         0.802           Categorical variables of basic information         (80         1024         58         0.001           Female         1082         1024         58         0.001           Male         1536         1351         185         0.202           No         2076         1891         185         0.001           Yes         542         484         58         0.016           Diabetes mellitus         2178         211         0.016           No         229         197         32         11           Yes         229         197         201         196           Smoking labits         7         2001         196         0.001           Smoker         421         374         47         0.001           No         2384         2171         213         0.001           Yes         234         204         30         0.001           New Cobstruction*         7         201         213         0.001           Yes         33         23         23         10         0.001					
Categorial variables of basic information					
Gender		6.1 (0–1000)	6.0 (0–1000)	7.0 (0–300)	0.802
Femule         1082         1024         58           Male         1336         1351         185           Hypertension         0.201           No         2076         1891         185           Yes         542         484         58           Diabetes mellius         0.010         105           No         2389         178         211           Yes         229         197         32           Smoking babits         197         2001         196           Smoker         421         374         47           Alcohol excess         2197         2001         196           Smoker         421         374         47           Alcohol excess         234         204         30           Bowel obstruction*         2384         2171         213         23           Smoker         33         23         23         10         2001           No         2585         2352         233         23         23         23         23         23         23         23         23         23         23         23         23         23         24         23         24 <td></td> <td></td> <td></td> <td></td> <td>&lt; 0.001</td>					< 0.001
Male         1536         1351         185           Hypertronion         2076         1891         185           Yes         542         484         58           Diabetes mellitus              No         2389         2178         211           No         2389         2178         211           Yes         229         197         32           Smoking balts              Normander         2197         2001         196           Smoker         421         374         47           Alcohol excess              No         2384         2171         213            Alcohol excess		1092	1024	50	< 0.001
Hypertension					
No         2076         1891         185           Yes         542         444         58           Diabetes mellims		1550	1331	163	0.201
Kys         542         484         58           Diabetes mellius         2389         2178         211           Yes         229         197         32           Smoking habits         201         374         47           Smoker         421         374         47           Alcohol exces         2884         2171         213           Yes         2384         2171         213           Yes         2384         2171         213           Yes         238         2352         233           Bowel obstruction*         7         0.001           No         2585         2352         23           Yes         33         23         10           ASA score         7         24         3           1         51         759         92           2         1192         1103         89           3         27         24         3           1         12         15         15         7           11         235         145         7         7           12         15         14         7         1 <td< td=""><td>**</td><td>2076</td><td>1801</td><td>185</td><td>0.201</td></td<>	**	2076	1801	185	0.201
Diabetes mellius					
No         2389         2178         211           Yes         229         197         32           Smoking habits         0.146           Nor-smoker         2197         2001         196           Smoker         421         374         47           Alcohol excess		342	404	36	0.010
Yes         229         197         32           Smoking habits         2197         2001         196           Smoker         421         374         47           Alcohol excess		2380	2178	211	0.010
Smoking habits					
Nosmoker   2197   2001   196   195		)	171	5 <u>2</u>	0.146
Smoker         421         374         47         Accordance constructions         0.051           NO         2384         2171         213         218         258         258         258         258         232         233         200         0.001		2107	2001	196	0.140
Alcohol excess					
No         2384         2171         213           Yes         234         204         30           Bowel obstruction*		721	374	77	0.051
Ves         234         204         30           Bowel obstruction"         2585         2352         233           Yes         3         23         10           ASA score         "0.036         10           1         851         759         92           2         1192         1103         89           3         27         24         3           7 stage         "0.114         7           Tis         152         145         7           T1         235         218         17           T2         561         505         56           T3         682         620         62           T4a         924         833         91           T4b         64         54         10           Natge         "0.05         56           No         1496         1358         138           N1         722         648         74           N2         400         369         31           Mstage         2413         2182         231           Mill         205         193         12           Tumor stage (TNM-s		2384	2171	213	0.051
Sove					
No         2885         2352         233           Yes         33         23         10           ASA score		231	201	30	< 0.001
Yes         33         23         10           ASA score         759         92           2         1192         1103         89           3         27         24         3           T stage         """"""""""""""""""""""""""""""""""""		2585	2352	233	0.001
ASA score    1					
1         851         759         92           2         1192         1103         89           3         27         24         3           T stage              T1         25         145         7           T1         235         218         17           T2         561         505         56           T3         682         620         62           T4a         924         833         91           T4b         64         54         10           N stage              N0         1496         1358         138           N1         722         648         74           N2         400         369         31           M stage              M stage              Mo         2413         2182         231           MI         205         193         12           Tumor stage (TNM-system)              Ti         5			25	10	0.030
2     1192     1103     89       3     27     24     3       T stage		851	759	92	0.020
3     27     24     3       T stage     0.114       Tis     152     145     7       T1     235     218     17       T2     561     505     56       T3     682     620     62       T4a     924     833     91       T4b     64     54     10       N stage     0     1496     1358     138       N0     1496     1358     138       N2     400     369     31       N2     400     369     31       MStage     5     231       MO     2413     2182     231       MI     205     193     12       Tumor stage (TNM-system)     12     0.085       Tis     151     144     7       I     597     536     61       III     671     608     63       III     994     894     100       IV     205     144     7       Categorical variables of treatment details     7     1       Neoadjuvant chemoradiation     2244     2041     203       No     2244     2041     203       Yes     374     334					
T stage         0.114           Tis         152         145         7           TI         235         218         17           T2         561         505         56           T3         682         620         62           T4a         924         833         91           T4b         64         54         10           Nstage					
Tis         152         145         7           T1         235         218         17           T2         561         505         56           T3         682         620         62           T4a         924         833         91           T4b         64         54         10           N stage         """"""""""""""""""""""""""""""""""""					0.114
T1         235         218         17           T2         561         505         56           T3         682         620         62           T4a         924         833         91           T4b         64         54         10           N stage		152	145	7	0.111
T2         561         505         56           T3         682         620         62           T4a         924         833         91           T4b         64         54         10           N stage         56         10           N0         1496         1358         138           N1         722         648         74           N2         400         369         31           M stage         2413         2182         231           M1         205         193         12           Tumor stage (TNM-system)         12         12           Tis         151         144         7           I         597         536         61           II         671         608         63           III         994         894         100           IV         205         144         7           Categorical variables of treatment details         7         1           No         2244         2041         203           Yes         374         334         40           Surgical approach         202         204					
T3         682         620         62           T4a         924         833         91           T4b         64         54         10           N stage         0.382           N0         1496         1358         138           N1         722         648         74           N2         400         369         31           M stage         5         5         0.078           M0         2413         2182         231           M1         205         193         12           Tumor stage (TNM-system)         597         536         61         1           II         597         536         61           II         671         608         63           III         994         894         100           IV         205         144         7           Categorical variables of treatment details         894         100           No         2244         2041         203           Yes         374         334         40           Surgical approach         202         204           Open         <					
T4a         924         833         91           T4b         64         54         10           N stage          0,382           N0         1496         1358         138           NI         722         648         74           N2         400         369         31           M stage          0,078           M0         2413         2182         231           MI         205         193         12           Tumor stage (TNM-system)              Tis         151         144         7           I         597         536         61           II         994         894         100           IV         205         144         7           Categorical variables of treatment details         No         2244         2041         203           Yes         374         334         40           Surgical approach             Open         2223         2004         219           Laparoscopic         395         371         24           Dive					
T4b     64     54     10       N stage     0.382       N0     1496     1358     138       N1     722     648     74       N2     400     369     31       M stage     0.078       M0     2413     2182     231       M1     205     193     12       Tumor stage (TNM-system)     0.089       Tis     151     144     7       I     597     536     61       II     597     536     63       III     994     894     100       IV     205     144     7       Categorical variables of treatment details     7     0.305       No     2244     2041     203       Yes     374     334     40       Surgical approach     2223     2004     219       Laparoscopic     395     371     24       Diverting stoma     2174     1972     202       Yes     444     403     41       Blood transfusion     0.572					
Nstage     0,382       N0     1496     1358     138       N1     722     648     74       N2     400     369     31       M stage					
NO					0.382
N1       722       648       74         N2       400       369       31         M stage       0.078         M0       2413       2182       231         M1       205       193       12         Tumor stage (TNM-system)       5       12         Tis       151       144       7         I       671       608       63         III       671       608       63         III       994       894       100         IV       205       144       7         Categorical variables of treatment details       63       11         No adjuvant chemoradiation       2244       2041       203         Yes       374       334       40         Surgical approach       2223       2004       219         Laparoscopic       395       371       24         Diverting stoma       100       1072       202         Yes       444       403       41         Blood transfusion       50.572		1496	1358	138	
N2     400     369     31       M stage     0.078       M0     2413     2182     231       M1     205     193     12       Tumor stage (TNM-system)					
Mstage     2413     2182     231       M1     205     193     12       Tumor stage (TNM-system)     0.085       Tis     151     144     7       I     597     536     61       II     671     608     63       III     994     894     100       IV     205     144     7       Categorical variables of treatment details     0.309       Neoadjuvant chemoradiation     2244     2041     203       Yes     374     334     40       Surgical approach     0pen     2223     2004     219       Laparoscopic     395     371     24       Diverting stoma     No     2174     1972     202       Yes     444     403     41       Blood transfusion     0.572					
M0     2413     2182     231       M1     205     193     12       Tumor stage (TNM-system)     0.085       Tis     151     144     7       I     597     536     61       II     671     608     63       III     994     894     100       IV     205     144     7       Categorical variables of treatment details     Vecadjuvant chemoradiation     2244     2041     203       Yes     374     334     40       Surgical approach     0pen     2223     2004     219       Laparoscopic     395     371     24       Diverting stoma     No     2174     1972     202       Yes     444     403     41       Blood transfusion     0.572					0.078
MI     205     193     12       Tumor stage (TNM-system)     0.085       Tis     151     144     7       I     597     536     61       II     671     608     63       III     994     894     100       IV     205     144     7       Categorical variables of treatment details       Nooadjuvant chemoradiation     50309       No     2244     2041     203       Yes     374     334     40       Surgical approach     5004     219       Laparoscopic     395     371     24       Diverting stoma     50970       No     2174     1972     202       Yes     444     403     41       Blood transfusion     50572		2413	2182	231	
Tumor stage (TNM-system)         Tis       151       144       7         I       597       536       61         II       671       608       63         III       994       894       100         IV       205       144       7         Categorical variables of treatment details         Neoadjuvant chemoradiation         No       2244       2041       203         Yes       374       334       40         Surgical approach       009       2004       219         Laparoscopic       395       371       24         Diverting stoma       0.970         No       2174       1972       202         Yes       444       403       41         Blood transfusion       0.572		205			
I       597       536       61         II       671       608       63         III       994       894       100         IV       205       144       7         Categorical variables of treatment details         No       2244       2041       203         Yes       374       334       40         Surgical approach       2223       2004       219         Laparoscopic       395       371       24         Diverting stoma       0.970         No       2174       1972       202         Yes       444       403       41         Blood transfusion       0.572	Tumor stage (TNM-system)				0.089
I       597       536       61         II       671       608       63         III       994       894       100         IV       205       144       7         Categorical variables of treatment details         No       2244       2041       203         Yes       374       334       40         Surgical approach       2223       2004       219         Laparoscopic       395       371       24         Diverting stoma       0.970         No       2174       1972       202         Yes       444       403       41         Blood transfusion       0.572	• •	151	144	7	
III       994       894       100         IV       205       144       7         Categorical variables of treatment details         Neoadjuvant chemoradiation					
IV     205     144     7       Categorical variables of treatment details     0.305       Neoadjuvant chemoradiation     0.305       No     2244     2041     203       Yes     374     334     40       Surgical approach     0.017       Open     2223     2004     219       Laparoscopic     395     371     24       Diverting stoma     0.970       No     2174     1972     202       Yes     444     403     41       Blood transfusion     0.572	II	671	608	63	
IV     205     144     7       Categorical variables of treatment details     0.305       Neoadjuvant chemoradiation     0.305       No     2244     2041     203       Yes     374     334     40       Surgical approach     0.017       Open     2223     2004     219       Laparoscopic     395     371     24       Diverting stoma     0.970       No     2174     1972     202       Yes     444     403     41       Blood transfusion     0.572	III	994	894	100	
Neoadjuvant chemoradiation         0.309           No         2244         2041         203           Yes         374         334         40           Surgical approach         0.017         0.017           Open         2223         2004         219           Laparoscopic         395         371         24           Diverting stoma         0.970           No         2174         1972         202           Yes         444         403         41           Blood transfusion         0.572			144	7	
Neoadjuvant chemoradiation         0.309           No         2244         2041         203           Yes         374         334         40           Surgical approach         0.017         0.017           Open         2223         2004         219           Laparoscopic         395         371         24           Diverting stoma         0.970           No         2174         1972         202           Yes         444         403         41           Blood transfusion         0.572	Categorical variables of treatment details				
No       2244       2041       203         Yes       374       334       40         Surgical approach       Open       2223       2004       219         Laparoscopic       395       371       24         Diverting stoma       No       2174       1972       202         Yes       444       403       41         Blood transfusion       Blood transfusion       0.572					0.309
Yes     374     334     40       Surgical approach     0.017       Open     2223     2004     219       Laparoscopic     395     371     24       Diverting stoma     0.970       No     2174     1972     202       Yes     444     403     41       Blood transfusion     0.572		2244	2041	203	
Open       2223       2004       219         Laparoscopic       395       371       24         Diverting stoma       0.970         No       2174       1972       202         Yes       444       403       41         Blood transfusion       0.572	Yes	374	334		
Open       2223       2004       219         Laparoscopic       395       371       24         Diverting stoma       0.970         No       2174       1972       202         Yes       444       403       41         Blood transfusion       0.572	Surgical approach				0.017
Laparoscopic     395     371     24       Diverting stoma     0.970       No     2174     1972     202       Yes     444     403     41       Blood transfusion     0.572		2223	2004	219	
Diverting stoma       0.970         No       2174       1972       202         Yes       444       403       41         Blood transfusion       0.572					
No       2174       1972       202         Yes       444       403       41         Blood transfusion       0.572					0.970
Yes         444         403         41           Blood transfusion         0.572		2174	1972	202	
Blood transfusion 0.572					
					0.572
	No	2585	2346	239	



Table 1 (continued)

Categorical variables	All patients ( $N = 2618$ )	Patients without AL $(N=2375)$	Patients with AL $(N = 243)$	P value
Yes	33	29	4	
Anastomotic bleeding <sup>b</sup>				< 0.001
No	2581	2354	227	
Yes	37	21	16	
Combined left/right hemicolectomy				0.079
No	2592	2354	238	
Yes	26	21	5	
Synchronous liver resection <sup>c</sup>				0.311
No	2608	2365	243	
Yes	10	10	0	

A two-tailed P value < 0.05 was considered statistically significant

BMI, body mass index; ASA, American Society of Anesthesiologists

less than 5–6 cm. Nevertheless, these studies could not accurately predict the corresponding risk of AL based on specific tumor locations. Our study identified the corresponding risk for AL based on specific tumor locations, and a nomogram model that could accurately identify the patients at high risk for AL was then created.

In previous studies, the association between tumor size and AL was investigated. A study by Park et al. [29] showed that the AL rate was significantly higher in patients with tumor sizes >4 cm compared with those with tumor sizes <4 cm. In the studies conducted by Yun et al. [10] and Koyama et al. [7], the classification criteria were defined as 3 cm and 5 cm, respectively. However, no significant difference in AL risk was observed between the different groups. Nevertheless, all these studies reported higher AL rates in the patient groups with larger tumor sizes than in those with smaller tumor sizes. The absence of statistically significant differences in these studies might be due to their relatively small sample sizes. In this study, tumor size was considered a continuous variable for

 Table 2
 Factors associated with anastomotic leakage after anterior resection for rectal cancer by multivariate analysis

	Adjusted OR (95% CI)	P value
Gender (male)	2.286 (1.484~3.520)	< 0.0001
Distance of tumor to anal verge	0.791 (0.75~0.864)	< 0.0001
Tumor size	1.175 (1.048~1.318)	0.006
Duration of operation	1.009 (1.005~1.013)	< 0.001
Diabetes mellitus	1.704 (1.023~2.837)	0.041
Surgical approach	0.445 (0.255~0.773)	0.004
Anastomotic bleeding	13.46 (5.640~31.63)	< 0.001
Diverting stoma	0.386 (0.234~0.636)	< 0.001

multivariate analysis, which showed that a larger tumor size was associated with a higher risk for AL.

The results of previous studies on whether intraoperative bleeding and blood transfusions increase the risk for AL have produced conflicting results [7, 24, 27, 28]. Our study showed that neither intraoperative bleeding nor blood transfusion increased the risk for AL. Only a few studies have investigated the relationship between AL and anastomotic bleeding, which was found in our study to be an independent risk factor for AL (adjusted OR = 11). Patients with anastomotic bleeding in both the training and validation cohorts had significantly higher risk for AL (P < 0.001). Anastomotic bleeding may be caused by the poor quality of the stapling device or improper use of the stapling device. All these factors may lead to increased AL risk.


The effects of neoadjuvant therapy on AL after rectal cancer resection have been controversial. In early clinical studies, most neoadjuvant radiotherapies were short-course regimens. A meta-analysis that included 7 clinical studies (including 4 with short-course radiotherapy) concluded that neoadjuvant radiotherapy did not increase the risk for AL [30]. With the increasing popularity of long-course radiotherapy as a neoadjuvant therapy, more recent clinical studies have shown that long-course neoadjuvant radiotherapy, particularly intensive chemoradiation therapy, increased the risk of AL [5, 28]. We believe that short-course radiotherapy does not cause significant bowel edema. In contrast, long-course radiotherapy, particularly intensive chemoradiation therapy, may cause significant bowel edema that increases the risk of AL. Therefore, whether the radiotherapy induced bowel edema and whether the anastomosis has been created in non-edematous areas during the surgery may be the reasons of the published discrepancy mentioned above.



<sup>&</sup>lt;sup>a</sup> Bowel obstruction was defined as obvious difficulty in defecation or radiologically confirmed obstruction and dilation of the proximal bowel

<sup>&</sup>lt;sup>b</sup> Anastomotic bleeding was defined as active bleeding at the anastomotic site before the end of surgery or postoperative blood stool with one or more of the following criteria: a significant fall in hemoglobin, need for blood transfusion, hemodynamic instability or shock and, finally, the need for any emergency intervention such as colonoscopy or surgery

<sup>&</sup>lt;sup>c</sup> Synchronous resection of both primary tumor and liver metastasis



**Fig. 1** A nomogram for predicting postoperative anastomotic leakage after anterior resection for rectal cancer. To estimate the probability of AL in a given patient, mark patient values at each axis, draw a straight line

perpendicular to the point axis, and sum the points for all variables. Then, we summed the total points and drew vertical line from the "total points" row to obtain the probability of anastomotic leakage

A diverting stoma (DS) is often constructed to prevent AL. However, whether a DS can reduce the AL rate remains controversial. Some previous studies reported that a stoma could reduce severe anastomotic leakage and that a diverting stoma can diminish the severity of the leakage [6, 31]. In a study by Matthiessen et al. [6], 234 patients who received LAR for rectal cancer were randomly assigned to undergo DS. The AL rate of patients with a DS was 10.3%, which is significantly lower than that in patients without a DS (28%). A metaanalysis [32] which included 4 randomized controlled studies and 9 nonrandomized studies in 2015 showed that the risk of AL was significantly lower in patients with DS. However, Shiomi et al. [24] found that the presence of a stoma could not reduce the incidence rate of AL but could reduce the reoperation rate by alleviating the clinical symptoms caused by AL. Wong et al. [3] reported that a diverting stoma could not reduce grades B and C AL.

On the other hand, the impact of a DS on quality of life, such as an uncomfortable smell, the need for special care, prolapse at the stoma site, and fecal dermatitis, should not be ignored. Moreover, patients with DS are more likely to suffer from stenosis at the anastomotic site as well as significant morbidity and even mortality during stoma reversal. Several temporary stomas may become permanent [13], especially in patients who received neoadjuvant radiochemotherapy. Thus, whether a protective stoma is necessary remains controversial.

We recommend identifying high-risk patients who might need colostomy using our nomogram model, which will increase the selectivity of stoma creation among patients receiving AR.

Duration of surgery is also regarded as a risk factor in some previous studies [8, 9, 17]. Our study also confirmed that patients with a longer duration of surgery had a higher risk of AL. The long duration of surgery may be caused by amateur surgical skill or poor exposure of the surgical field due to pelvic stenosis or large tumor. In addition, a decrease in blood perfusion caused by prolonged anesthesia may also increase the risk of AL.

Previous studies reported that diabetes mellitus (DM) was a risk factor for AL [11, 33]. We also got the same conclusion (OR, 1.7). The reasons why type 2 DM increased the risk of AL are as follows: insufficient blood supply to the anastomosis due to microcirculatory disorders, insufficient glycogen stores, and delayed tissue healing due to hyperglycemia. Therefore, patients with type 2 DM should be ensured that blood glucose is well controlled before surgery to reduce the risk of AL. However, several studies found that diabetes was not a risk factor for AL [27, 34].

Whether laparoscopic surgery increases the risk of anastomotic leakage is also controversial. Laparoscopic surgery does not reinforce the anastomosis conventionally, especially in low and ultralow anterior resection, which may



 Table 3
 Univariate analysis of variables related to anastomotic leakage (test dataset)

Categorical variables	All patients $(N = 611)$	Patients without AL $(N = 547)$	Patients with AL $(N = 64)$	P value
Continuous variables				
Age, year (range)	58.7 (24–86)	58.7 (24–86)	59.1 (30–82)	0.789
BMI, kg/m <sup>2</sup> (range)	23.5 (15.4–36.6)	23.5 (15.4–33.7)	23.7 (15.6–36.6)	0.572
Distance of tumor to anal verge, cm (range)	8.0 (3.5–12.0)	8.1 (3.5–12.0)	7.7 (3.5–12.0)	0.236
Tumor size, cm (range)	4.0 (0.5–12.0)	3.9 (0.5–12)	4.2 (1.5–8.0)	0.090
Duration of operation, min (range)	108.9 (27–385)	115.4 (28–385)	126.5 (50–255)	0.081
Preoperative hemoglobin, g/L	131.9 (67–170)	131.3 (67–169)	131.8 (96–170)	0.835
Preoperative albumin, g/L				0.353
1	43.2 (29.4–52.3)	43.3 (29.4–52.3)	42.8 (34.9–50.4)	
Blood lost, mL (range)	55.0 (5–1200)	54.9 (5–1200)	56.5 (5–150)	0.841
Perioperative blood transfusion, mL (range)	6.1 (0–1000)	5.8 (0–1000)	7.8 (0–500)	0.811
Categorical variables of basic information				
Gender				< 0.001
Male	228	217	11	
Female	383	330	53	
Hypertension				0.078
No	542	481	61	0.070
Yes	69	66	3	
Diabetes mellitus				< 0.001
No	571	521	50	
Yes	40	26	14	
Smoking habits				0.424
Non-smoker	524	467	57	0.121
Smoker	87	80	7	
	87	80	/	0.000
Alcohol excess				0.899
No	551	493	58	
Yes	60	54	6	
Bowel obstruction <sup>a</sup>				< 0.001
No	577	523	54	
Yes	34	24	10	
ASA score	J.		10	0.316
	200	172	27	0.510
1		173		
2	380	345	35	
3	24	22	2	
T stage				0.185
Tis	33	29	4	
T1	59	52	7	
T2	130	116	14	
T3	78	73	5	
T4a	283	250	33	
T4b	28	27	1	
N stage				0.372
N0	362	320	42	
N1	170	153	17	
N2	79	74	5	
M stage	,,	, .		0.714
=	552	495	57	0.714
M0				
M1	59	52	7	
Tumor stage (TNM-system)				0.676
Tis	31	27	4	
I	153	137	16	
II	149	130	19	
III	219	201	18	
IV	59	52	7	
	39	32	/	
Categorical variables of treatment details Neoadjuvant chemoradiation				0.536
·	470	426	50	0.550
No	478	426	52	
Yes	133	121	12	
Surgical approach				0.462
Open	346	307	39	
Laparoscopic	265	240	25	
Diverting stoma				0.860
				3.000
	388	348	40	
No Yes	388 223	348 199	40 24	



Table 3 (continued)

Categorical variables	All patients $(N = 611)$	Patients without AL $(N = 547)$	Patients with AL $(N = 64)$	P value
Blood transfusion				0.741
No	604	541	63	
Yes	7	6	1	
Anastomotic bleeding <sup>b</sup>				< 0.001
No	598	539	59	
Yes	13	8	5	
Combined left/right hemicolectomy				0.485
No	606	543	63	
Yes	5	4	1	
Synchronous liver resection <sup>c</sup>				0.363
No	604	540	64	
Yes	7	7	0	


A two-tailed P value < 0.05 was considered statistically significant


BMI, body mass index; ASA, American Society of Anesthesiologists


increase the risk of anastomotic leakage. However, the CLASSIC study found that the incidence of AL was similar in laparoscopic and open surgery groups either in all enrolled patients (4% and 3%) or in the rectal cancer subgroup (8% and 7%) [35, 36]. Similarly, the COLORII study did not find that laparoscopic surgery increased the incidence of anastomotic leakage after radical resection of rectal cancer (12.6% and 10.4%, P = 0.462) [37]. A metanalysis including 11 nonrandomized controlled trials and 7 randomized controlled trials reported a 7.6% incidence of anastomotic leakage after laparoscopic surgery, with no significant difference compared with 8.9% of anastomotic leakage after open surgery [38]. In our study, we found that

laparoscopic surgery can reduce the incidence of anastomotic leakage. The reason may be explained by a better pelvis exposure of the surgical field, which leads to a better protection of the bowel in laparoscopic surgery.

This study had some limitations due to its retrospective nature. However, our nomogram could provide the surgeon with the precise probability of anastomotic leakage after low anterior resection for rectal cancer. Our nomogram can remind the surgeon to take precautions of patients with high AL risk. When patients with higher probability of anastomotic leakage are identified by the nomogram, they should be monitored carefully during the postoperative period. It might be helpful for them to delay removal of drainage tubes. In addition, the







had a bootstrapped-concordance index of 0.72 and was well calibrated. **b** We validated the nomograms with an external independent validation set, and the receiver operating characteristic curve for the prediction model area under the curve was 0.723



<sup>&</sup>lt;sup>a</sup> Bowel obstruction was defined as obvious difficulty in defecation, or radiologically confirmed obstruction and dilation of the proximal bowel

<sup>&</sup>lt;sup>b</sup> Anastomotic bleeding was defined as active bleeding at the anastomotic site before the end of surgery or postoperative blood stool with one or more of the following criteria: a significant fall in hemoglobin, need for blood transfusion, hemodynamic instability or shock and, finally, the need for any emergency intervention such as colonoscopy or surgery

<sup>&</sup>lt;sup>c</sup> Synchronous resection of both primary tumor and liver metastasis

nomogram can also avoid an unnecessary DS in patients with low risk of AL, which reduces the quality of life and increases economic burden, as well as the risk of a permanent stoma. Our tools help to achieve more rational allocation of medical resources.

In conclusion, our study proved that a protective diverting stoma and laparoscopic surgery significantly decrease the risk of anastomotic leakage. Our nomogram was a useful tool for precise prediction of anastomotic leakage after anterior resection for rectal cancer.

Acknowledgments We appreciate much support, including case collection and management, from all of the surgeons in Fudan University Cancer Center. The study group was as follows: Xinxiang Li, Weilie Gu, Zuqing Guan, Guoxiang Cai, Minghe Wang, Peng Lian, Junjie Peng, Debing Shi, Lei Liang, Liyong Huang, Fangqi Liu, Dawei Li, Sheng Wang, Yiwei Li, Qingguo Li, Xiaoji Ma, Renjie Wang, and Yanlei Ma.

The contribution of each author Hongtu Zheng: conceptualization, data curation, formal analysis, investigation, methodology, project administration, resources, writing—original draft

Zhenyu Wu: data curation, formal analysis, methodology, software, supervision, writing—review and editing

Yuchen Wu: data curation, investigation, resources, writing—review and editing

Shanjing Mo: conceptualization, methodology, supervision, writing—review and editing

Weixing Dai: data curation, formal analysis, methodology, software, writing—review and editing

Fangqi Liu: conceptualization, investigation, methodology, supervision, writing—review and editing

Ye Xu: conceptualization, methodology, supervision, writing—review and editing

Sanjun Cai: conceptualization, methodology, supervision, writing—review and editing

# **Compliance with ethical standards**

This study was approved by the Research Ethics Committee of the Cancer Hospital, Fudan University. Collection of patients' follow-up data was conducted in accordance with guidelines for the collection of human follow-up data from the Cancer Hospital, Fudan University. All patients provided written informed consent.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

### References

 Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014[J]. CA Cancer J Clin 64(2):104–117

- Maggiori L, Bretagnol F, Lefevre JH et al (2011) Conservative management is associated with a decreased risk of definitive stoma after anastomotic leakage complicating sphincter-saving resection for rectal cancer[J]. Color Dis 13(6):632–637
- Wong NY, Eu KW (2005) A defunctioning ileostomy does not prevent clinical anastomotic leak after a low anterior resection: a prospective, comparative study [J]. Dis Colon Rectum 48(11): 2076–2079
- Yeh CY, Changchien CR, Wang JY et al (2005) Pelvic drainage and other risk factors for leakage after elective anterior resection in rectal cancer patients: a prospective study of 978 patients [J]. Ann Surg 241(1):9–13
- Eriksen MT, Wibe A, Norstein J et al (2005) Anastomotic leakage following routine mesorectal excision for rectal cancer in a national cohort of patients [J]. Color Dis 7(1):51–57
- Matthiessen P, Hallbook O, Rutegard J et al (2007) Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial [J]. Ann Surg 246(2):207–214
- Koyama M, Murata A, Sakamoto Y et al (2016) Risk factors for anastomotic leakage after intersphincteric resection without a protective defunctioning stoma for lower rectal cancer [J]. Ann Surg Oncol 23(Suppl 2):S249

  S256
- Rencuzogullari A, Benlice C, Valente M et al (2017) Predictors of anastomotic leak in elderly patients after colectomy: nomogrambased assessment from the American College of Surgeons National Surgical Quality Program procedure-targeted cohort [J]. Dis Colon Rectum 60(5):527–536
- Yao HH, Shao F, Huang Q et al (2014) Nomogram to predict anastomotic leakage after laparoscopic anterior resection with intracorporeal rectal transection and double-stapling technique anastomosis for rectal cancer[J]. Hepatogastroenterology 61(133): 1257–1261
- Yun JA, Cho YB, Park YA et al (2017) Clinical manifestations and risk factors of anastomotic leakage after low anterior resection for rectal cancer[J]. ANZ J Surg 87(11):908-914
- Zhang W, Lou Z, Liu Q, Meng R, Gong H, Hao L, Liu P, Sun G, Ma J, Zhang W (2017) Multicenter analysis of risk factors for anastomotic leakage after middle and low rectal cancer resection without diverting stoma: a retrospective study of 319 consecutive patients [J]. Int J Color Dis 32:1431–1437
- Lu ZR, Rajendran N, Lynch AC et al (2016) Anastomotic leaks after restorative resections for rectal cancer compromise cancer outcomes and survival [J]. Dis Colon Rectum 59(3):236–244
- Kim MJ, Kim YS, Park SC et al (2016) Risk factors for permanent stoma after rectal cancer surgery with temporary ileostomy [J]. Surgery 159(3):721–727
- Krarup PM, Nordholm-Carstensen A, Jorgensen LN et al (2015) Association of comorbidity with anastomotic leak, 30-day mortality, and length of stay in elective surgery for colonic cancer: a nationwide cohort study [J]. Dis Colon Rectum 58(7):668–676
- Alves A, Panis Y, Trancart D et al (2002) Factors associated with clinically significant anastomotic leakage after large bowel resection: multivariate analysis of 707 patients[J]. World J Surg 26(4): 499–502
- Mirnezami A, Mirnezami R, Chandrakumaran K et al (2011) Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and metaanalysis[J]. Ann Surg 253(5):890–899
- Dekker JW, Liefers GJ, de Mol VOJ et al (2011) Predicting the risk of anastomotic leakage in left-sided colorectal surgery using a colon leakage score[J]. J Surg Res 166(1):e27–e34
- Frasson M, Flor-Lorente B, Rodriguez JL et al (2015) Risk factors for anastomotic leak after colon resection for cancer: multivariate analysis and nomogram from a multicentric, prospective, national study with 3193 patients[J]. Ann Surg 262(2):321–330



- Kim CH, Lee SY, Kim HR et al (2017) Nomogram prediction of anastomotic leakage and determination of an effective surgical strategy for reducing anastomotic leakage after laparoscopic rectal cancer surgery[J]. Gastroenterol Res Pract 2017:4510561
- Rahbari NN, Weitz J, Hohenberger W et al (2010) Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer[J]. Surgery 147(3):339–351
- Harrell FJ, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors[J]. Stat Med 15(4): 361–387
- Iasonos A, Schrag D, Raj GV et al (2008) How to build and interpret a nomogram for cancer prognosis[J]. J Clin Oncol 26(8):1364– 1370
- Park JS, Huh JW, Park YA et al (2016) Risk factors of anastomotic leakage and long-term survival after colorectal surgery[J]. Medicine (Baltimore) 95(8):e2890
- Shiomi A, Ito M, Maeda K et al (2015) Effects of a diverting stoma on symptomatic anastomotic leakage after low anterior resection for rectal cancer: a propensity score matching analysis of 1,014 consecutive patients[J]. J Am Coll Surg 220(2):186–194
- Qin Q, Ma T, Deng Y et al (2016) Impact of preoperative radiotherapy on anastomotic leakage and stenosis after rectal cancer resection: post hoc analysis of a randomized controlled trial[J]. Dis Colon Rectum 59(10):934–942
- Smith JD, Paty PB, Guillem JG et al (2012) Anastomotic leak is not associated with oncologic outcome in patients undergoing low anterior resection for rectal cancer[J]. Ann Surg 256(6):1034–1038
- Akiyoshi T, Ueno M, Fukunaga Y et al (2011) Incidence of and risk factors for anastomotic leakage after laparoscopic anterior resection with intracorporeal rectal transection and double-stapling technique anastomosis for rectal cancer[J]. Am J Surg 202(3):259–264
- Jestin P, Pahlman L, Gunnarsson U (2008) Risk factors for anastomotic leakage after rectal cancer surgery: a case-control study[J]. Color Dis 10(7):715–721
- Park JS, Choi GS, Kim SH et al (2013) Multicenter analysis of risk factors for anastomotic leakage after laparoscopic rectal cancer

- excision: the Korean laparoscopic colorectal surgery study group[J]. Ann Surg 257(4):665–671
- Qin C, Ren X, Xu K et al (2014) Does preoperative radio(chemo)therapy increase anastomotic leakage in rectal cancer surgery? A meta-analysis of randomized controlled trials[J]. Gastroenterol Res Pract 2014:910956
- Mrak K, Uranitsch S, Pedross F et al (2016) Diverting ileostomy versus no diversion after low anterior resection for rectal cancer: a prospective, randomized, multicenter trial[J]. Surgery 159(4):1129– 1139
- Gu WL, Wu SW (2015) Meta-analysis of defunctioning stoma in low anterior resection with total mesorectal excision for rectal cancer: evidence based on thirteen studies [J]. World J Surg Oncol 13:9
- Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, Moran B, Hanna GB, Mortensen NJ, Tekkis PP (2018) Incidence and risk factors for anastomotic failure in 1594 patients treated by transanal total mesorectal excision: results from the International TaTME Registry[J]. Ann Surg. https://doi.org/10.1097/SLA. 000000000000002653
- Hoshino N, Hida K, Sakai Y et al (2018) Nomogram for predicting anastomotic leakage after low anterior resection for rectal cancer[J]. Int J Color Dis 33(4):411–418
- Guillou PJ, Quirke P, Thorpe H et al (2005) Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial[J]. Lancet 365(9472):1718–1726
- Jayne DG, Thorpe HC, Copeland J et al (2010) Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer[J]. Br J Surg 97(11):1638–1645
- van der Pas MH, Haglind E, Cuesta MA et al (2013) Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial[J]. Lancet Oncol 14(3):210– 218
- Arezzo A, Passera R, Scozzari G et al (2013) Laparoscopy for rectal cancer reduces short-term mortality and morbidity: results of a systematic review and meta-analysis[J]. Surg Endosc 27(5):1485– 1502

